Jounce Therapeutics Inc. (NASDAQ:JNCE) went up by 12.67% from its latest closing price compared to the recent 1-year high of $14.84. The company’s stock price has collected -1.37% of loss in the last five trading sessions. Press Release reported on 09/02/21 that Jounce Therapeutics to Present at Upcoming Investor Conferences in September
Is It Worth Investing in Jounce Therapeutics Inc. (NASDAQ :JNCE) Right Now?
Plus, the 36-month beta value for JNCE is at 1.10. Opinions of the stock are interesting as 3 analysts out of 8 who provided ratings for Jounce Therapeutics Inc. declared the stock was a “buy,” while 2 rated the stock as “overweight,” 2 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $14.50. JNCE currently public float of 41.88M and currently shorts hold a 4.17% ratio of that float. Today, the average trading volume of JNCE was 477.50K shares.
JNCE’s Market Performance
JNCE stocks went down by -1.37% for the week, with a monthly jump of 20.93% and a quarterly performance of -7.44%, while its annual performance rate touched -21.95%. The volatility ratio for the week stands at 4.61% while the volatility levels for the past 30 days are set at 5.44% for Jounce Therapeutics Inc.. The simple moving average for the period of the last 20 days is 19.98% for JNCE stocks with a simple moving average of -11.96% for the last 200 days.
Analysts’ Opinion of JNCE
Many brokerage firms have already submitted their reports for JNCE stocks, with Raymond James repeating the rating for JNCE by listing it as a “Outperform.” The predicted price for JNCE in the upcoming period, according to Raymond James is $10 based on the research report published on September 14th of the current year 2021.
Piper Sandler, on the other hand, stated in their research note that they expect to see JNCE reach a price target of $20. The rating they have provided for JNCE stocks is “Overweight” according to the report published on March 15th, 2021.
H.C. Wainwright gave a rating of “Buy” to JNCE, setting the target price at $11 in the report published on December 04th of the previous year.
JNCE Trading at 26.65% from the 50-Day Moving Average
After a stumble in the market that brought JNCE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.88% of loss for the given period.
Volatility was left at 5.44%, however, over the last 30 days, the volatility rate increased by 4.61%, as shares surge +41.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.19% upper at present.
During the last 5 trading sessions, JNCE rose by +13.71%, which changed the moving average for the period of 200-days by +10.31% in comparison to the 20-day moving average, which settled at $6.18. In addition, Jounce Therapeutics Inc. saw -7.57% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at JNCE starting from Third Rock Ventures II, L.P., who sale 552,520 shares at the price of $8.00 back on May 25. After this action, Third Rock Ventures II, L.P. now owns 5,947,829 shares of Jounce Therapeutics Inc., valued at $4,420,160 using the latest closing price.
Higgons John Duncan, the Director of Jounce Therapeutics Inc., sale 200 shares at $10.00 during a trade that took place back on Apr 15, which means that Higgons John Duncan is holding 9,713 shares at $2,000 based on the most recent closing price.
Stock Fundamentals for JNCE
Current profitability levels for the company are sitting at:
- -72.37 for the present operating margin
The net margin for Jounce Therapeutics Inc. stands at -70.33. The total capital return value is set at -21.35, while invested capital returns managed to touch -21.06. Equity return is now at value -9.10, with -8.10 for asset returns.
Based on Jounce Therapeutics Inc. (JNCE), the company’s capital structure generated 7.99 points at debt to equity in total, while total debt to capital is 7.40. Total debt to assets is 6.92, with long-term debt to equity ratio resting at 6.45. Finally, the long-term debt to capital ratio is 5.97.
When we switch over and look at the enterprise to sales, we see a ratio of 0.94, with the company’s debt to enterprise value settled at 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.94.